Borosil Scientific Limited

rs,

August 12, 2025 BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001 The National Stock Exchange of India Limited Exchange Plaza, C-1,

8.5GW

ic Ltd INDIA’s first and largest solar glass manufacturer with a combined capacity of 1350 TPD (~8.5GW) ₹7784*cr Market Cap Note: *As on 8th Aug 2025- NSE One of the Market leaders in Consumer ware a

₹7784

INDIA’s first and largest solar glass manufacturer with a combined capacity of 1350 TPD (~8.5GW) ₹7784*cr Market Cap Note: *As on 8th Aug 2025- NSE One of the Market leaders in Consumer ware and Kitc

₹3871

ne of the Market leaders in laboratory glassware and Scientific instruments and Process sciences ₹3871*cr Market Cap ₹1386*cr Market Cap 3 A Legacy of more than 6 decades… Current Indian promoters

₹1386

ers in laboratory glassware and Scientific instruments and Process sciences ₹3871*cr Market Cap ₹1386*cr Market Cap 3 A Legacy of more than 6 decades… Current Indian promoters took over Entry in

₹2.59 crore

Note: 1. 2. EBITDA in Q1 FY26 declined due to lower sales and an IND AS 115 accounting impact of ₹2.59 crores compared to Q1 FY25 The Company had introduced a Voluntary Retirement Scheme (VRS) for the eligibl

₹6.61 crore

ting these workers. The settlement, including related professional fees, resulted in an expense of ₹6.61 crores, which is an exceptional item. 10 Particulars (₹ Crs)Q1FY26Q1FY25YoY%Q1FY26Q1FY25YoY%Net Sales89

5.1%

is an exceptional item. 10 Particulars (₹ Crs)Q1FY26Q1FY25YoY%Q1FY26Q1FY25YoY%Net Sales89.0 93.8 -5.1%96.0 104.6 -8.2%EBITDA (Note 1)11.9 13.1 -9.0%7.8 12.0 -35.0%EBITDA (%)13.4%14.0%8.1%11.5%EBIT (Note

8.2%

l item. 10 Particulars (₹ Crs)Q1FY26Q1FY25YoY%Q1FY26Q1FY25YoY%Net Sales89.0 93.8 -5.1%96.0 104.6 -8.2%EBITDA (Note 1)11.9 13.1 -9.0%7.8 12.0 -35.0%EBITDA (%)13.4%14.0%8.1%11.5%EBIT (Note 1)7.5 8.9 -16.2

9.0%

s)Q1FY26Q1FY25YoY%Q1FY26Q1FY25YoY%Net Sales89.0 93.8 -5.1%96.0 104.6 -8.2%EBITDA (Note 1)11.9 13.1 -9.0%7.8 12.0 -35.0%EBITDA (%)13.4%14.0%8.1%11.5%EBIT (Note 1)7.5 8.9 -16.2%2.9 7.4 -60.7%PBT (Note 1&2)0

35.0%

YoY%Q1FY26Q1FY25YoY%Net Sales89.0 93.8 -5.1%96.0 104.6 -8.2%EBITDA (Note 1)11.9 13.1 -9.0%7.8 12.0 -35.0%EBITDA (%)13.4%14.0%8.1%11.5%EBIT (Note 1)7.5 8.9 -16.2%2.9 7.4 -60.7%PBT (Note 1&2)0.7 8.7 -92.3%-4

13.4%

5YoY%Net Sales89.0 93.8 -5.1%96.0 104.6 -8.2%EBITDA (Note 1)11.9 13.1 -9.0%7.8 12.0 -35.0%EBITDA (%)13.4%14.0%8.1%11.5%EBIT (Note 1)7.5 8.9 -16.2%2.9 7.4 -60.7%PBT (Note 1&2)0.7 8.7 -92.3%-4.1 7.0 -158.1%P

“EBITDA in Q1 FY26 declined due to lower sales and an IND AS 115 accounting impact of ₹2.59 crores compared to Q1 FY25 The Company had introduced a Voluntary Retirement Scheme (VRS) for the eligible workers at its Ambad, Nashik plant.”

“Our sales team is actively addressing the export shortfall by accelerating domestic market penetration, and we expect to see positive traction from these efforts in the coming quarters.”

“Some of the key customers’ order got delayed and their execution is deferred to Q3 FY26 due to various reasons and hence the sale in Q1 FY26 got impacted.”

“Encouragingly, fresh order bookings in Q1 FY26 were substantially higher than last year, supported by initiatives in new product development, customer base expansion, talent strengthening, and operational efficiency improvements, aimed at boosting future sales and profitability.”

Note

2

Sub

1

Estimated Market Growth

1

Sub

Investor presentation on the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2025 Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the presentation on the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2025. The said presentation is also hosted on the Company's website at Investor Presentation - Borosil Scientific. Please take the above on record. Thanking You, Yours faithfully, For Borosil Scientific Limited Sanjay Gupta Company Secretary & Compliance Officer ICSI Membership No.: A24641 Encl: as above Q1FY26 Safe Harbour This investor presentation has been prepared by Borosil Scientific Limited (“Company”) on a strictly confidential basis. Certain statements in this presentation may be ‘forward looking statements’ within the meaning of applicable laws and regulations. These forw

Note

1. 2. EBITDA in Q1 FY26 declined due to lower sales and an IND AS 115 accounting impact of ₹2.59 crores compared to Q1 FY25 The Company had introduced a Voluntary Retirement Scheme (VRS) for the eligible workers at its Ambad, Nashik plant. In Q1FY26, the Company entered into a Memorandum of Settlement with the Bhartiya Kamgar Sena (BKS), the registered trade union representing these workers. The settlement, including related professional fees, resulted in an expense of ₹6.61 crores, which is an exceptional item. 10 Particulars (₹ Crs)Q1FY26Q1FY25YoY%Q1FY26Q1FY25YoY%Net Sales89.0 93.8 -5.1%96.0 104.6 -8.2%EBITDA (Note 1)11.9 13.1 -9.0%7.8 12.0 -35.0%EBITDA (%)13.4%14.0%8.1%11.5%EBIT (Note 1)7.5 8.9 -16.2%2.9 7.4 -60.7%PBT (Note 1&2)0.7 8.7 -92.3%-4.1 7.0 -158.1%PAT (Note 1&2)0.5 6.5 -92.9%-4.2 5.0 -183.8%Net Debt - period end(124.7) (4.0) (116.8) 2.6StandaloneConsolidated Category wise Sales Q1FY26 (Consolidated)

Note

1. 2. Lab Consumables domestic sales performed well; however, overall sales has been impacted due to degrowth in export sales and impact of IndAS 115. Export sales were impacted by the uncertainty surrounding U.S. import tariffs during Q1 FY26. Our sales team is actively addressing the export shortfall by accelerating domestic market penetration, and we expect to see positive traction from these efforts in the coming quarters. Process System had a revenue degrowth due to a significantly lower opening order book as of 1st April 2025 compared to the prior year. Some of the key customers’ order got delayed and their execution is deferred to Q3 FY26 due to various reasons and hence the sale in Q1 FY26 got impacted. Encouragingly, fresh order bookings in Q1 FY26 were substantially higher than last year, supported by initiatives in new product development, customer base expansion, talent strengthening, and operational efficiency improvements, aimed at boosting future sales and profitability.

Estimated Market Growth

6% to 8% Estimated Market Growth : 12% to 14% Glassware Segment Pharmaceutical Primary Packaging Serviceable Addressable Market : ₹1377 Cr Estimated Market Growth : 9%to10% Source: F&S 2019 report, Industry & Internal Estimates 15 New Product Development Fat with randall Fiber with fiber bags Moisture analyser Handheld Photometer Vial Inserts Micro Vials UV Visible Spectrophotometer e-dispenser e-Titrate Over head Stirrer Hot plate stirrer Quartz Distillation Unit 16 Emphasis on Environmental Testing Products Chemical Analysis Inorganic | Metal | Heavy Metals Electrochemistry Prime Lab 2.0 COD Digestor pH Meter Cond / TDS Meter Dissolved Oxygen Meter BOD System Comparator Tests Chemistry Kits Turbidity Meter 17 ISI Glassware Certification Achieved within 6 Months NO. 1 IN KJELDAHL Approx 750+ installations in a 5 Years Patented Bottle Top Dispenser DIY CALIBRATION A PATENTED PRODUCT 8000+ in last 3 years Worldwide Product Presence 90+ Countries Laboratory Glassware Pharma Primary Packi